| EVAMPLIX AGENUS INC.
1982692 01 Jul 2019 | on 31 Dec 1969 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical, therapeutic and biopharmaceutical agents for the treatment of cancer, infectious diseases, namely, respiratory infections, viruses, bacterial infections, parasitic diseases, and fungal infections and autoimmune disorders, transplant rejections, and inflammatory diseases, namely, asthma, celiac disease, inflammatory bowel disease, and inflammatory connective tissue diseases; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of cancer, infectious diseases, namely, respiratory infections, viruses, bacterial infections, parasitic diseases, and fungal infections and autoimmune disorders, transplant rejections, and inflammatory diseases, namely, asthma, celiac disease, inflammatory bowel disease, and inflammatory connective tissue diseases; biological preparations, namely, antibodies for the treatment of cancer, infectious diseases, namely, respiratory infections, viruses, bacterial infections, parasitic diseases, and fungal infections and autoimmune disorders, transplant rejections, and inflammatory diseases, namely, asthma, celiac disease, inflammatory bowel disease, and inflammatory connective tissue diseases. | | | EVAMPLIX (BALSTILIMAB) AGENUS INC.
2170281 19 Jan 2022 | on 31 Dec 1969 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical, therapeutic and biopharmaceutical agents for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; biological preparations, namely, antibodies for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases. | | 
